Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Aug 11:3:71-8.
doi: 10.2147/BCTT.S20695. eCollection 2011.

The p53 breast cancer tissue biomarker in Indian women

Vinayak W Patil  1 , Mukund B Tayade  2 , Sangeeta A Pingale  1 , Shubhangi M Dalvi  1 , Rajesh B Rajekar  1 , Hemkant M Deshmukh  1 , Shital D Patil  1 , Rajeev Singhai  1
Affiliations

The p53 breast cancer tissue biomarker in Indian women

Vinayak W Patil et al. Breast Cancer (Dove Med Press). .

Retraction in

  • Retraction.
    [No authors listed] [No authors listed] Breast Cancer (Dove Med Press). 2012 Mar 8;4:33. doi: 10.2147/BCTT.S31163. eCollection 2012. Breast Cancer (Dove Med Press). 2012. PMID: 24367192 Free PMC article. No abstract available.

Abstract

Background: Combination chemotherapy is highly effective in locally advanced breast cancer. A negative expression of biomarker p53 indicates a higher chance of responding to this regimen. Patients' p53 status may be used as a biological cancer marker to identify those who would benefit from more aggressive treatments.

Aims: The role of p53 in modulating apoptosis has suggested that it may affect the efficacy of anticancer agents. p53 alterations in 80 patients with locally advanced breast cancer IIIB undergoing neoadjuvant chemotherapy were prospectively evaluated.

Materials and methods: Patients received three cycles of paclitaxel (175 mg/m(2)) and doxorubicin (60 mg/m(2)) every 21 days. Tumor sections were analyzed before treatment for altered patterns of p53 expression, using immunohistochemistry and DNA sequencing.

Results: An overall response rate of 83.5% was obtained, including 15.1% complete pathological responses. The regimen was well tolerated with 17.7% grade 2/3 nausea and 12.8% grade 3/4 leukopenia. There was a statistically significant correlation between response and expression of p53. Of 25 patients who obtained a complete clinical response, only two were classified as p53-positive (P = 0.004, χ(2)). Of 11 patients who obtained a complete pathological remission, one was positive (P = 0.099, χ(2)).

Conclusion: Immunohistochemical (IHC) analysis has been shown to be a prognostic factor for patients with breast cancer in India. Paclitaxel is one of the most promising anticancer agents for the therapy of breast cancer, where it has also shown activity in tumors resistant to doxorubicin.

Keywords: breast cancer; cancer tissue biomarkers; doxorubicin; immunohistochemistry; infiltrating duct cancer; neoadjuvant chemotherapy; p53; paclitaxel.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Immunostaining of infiltrating duct breast cancer, 400× objective magnification; (A) dark brown positive nuclear staining for p53 and (B) negative nuclear staining for p53.
Figure 2
Figure 2
p53 expression and response to preoperative chemotherapy.
Figure 3
Figure 3
Overall survival for all patients and p53 expression by immunohistochemistry in breast cancer in a group of Indian women.
Figure 4
Figure 4
Overall survival for all patients with respect to the presence of residual tumor.
See this image and copyright information in PMC

References

    1. Holmes FA, Valero V, Walters RS, et al. Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results. Ann Oncol. 1999;10(4):403–411. - PubMed
    1. Holmes FA, Madden T, Newman RA, et al. Sequence dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 1996;14(10):2713–2721. - PubMed
    1. Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol. 2000;13(11):2688–2699. - PubMed
    1. Horwitz SB. Taxol (paclitaxel): mechanisms of action. Ann Oncol. 1994;5(Suppl 6):S3–S6. - PubMed
    1. Motwani M, Delohery TM, Schwartz GK. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Cancer Res. 1999;5(7):1876–1883. - PubMed

Publication types